Leonard, M. Z. | bioRxiv Science

bioRxiv2026

Repeated cocaine reorganizes striatal ensembles along the ventral-dorsal axis

Drugs of abuse produce lasting adaptations in the striatum. A prominent theory holds that the early reinforcing effects of cocaine preferentially engage the ventral striatum, and repeated cocaine use recruits dorsal striatal systems associated with habitual drug-related behavior. However, this transition has largely been conceptualized on the population level, obscuring how it is implemented within individual neurons and how repeated drug exposure reorganizes drug responsivity within these circuits. Here, we used single-cell calcium imaging to examine ventral and dorsal striatal responses to acute and repeated cocaine exposure in mice. Cocaine broadly suppressed neuronal activity throughout the ventral and dorsal striatum. However, repeated exposure produced opposing changes in cocaine-modulated neurons across the ventral-dorsal axis. The cocaine-activated population was reduced ventrally while expanding dorsally. Unique to dorsal striatum, repeated cocaine engendered two distinct features of activity: 1) Cocaine-activated cells had weak baseline coupling with the surrounding neuronal population and 2) The emergence of a subpopulation of neurons exhibiting regular, slow rhythmic activity in response to cocaine. Thus, repeated cocaine effects reflect a change in how the circuit is organized rather than simply how strongly it is engaged. This organization may allow cocaine to engage patterns of dorsal striatal activity that are largely absent under baseline conditions, creating a circuit state that becomes increasingly specific to the presence of the drug.

neuroscience↗

bioRxiv2024

Systemic inhibition of de novo purine biosynthesis prevents weight gain and improves metabolic health by increasing thermogenesis and decreasing food intake

ObjectiveObesity is a major health concern, largely because it contributes to type 2 diabetes mellitus (T2DM), cardiovascular disease, and various malignancies. Increase in circulating amino acids and lipids, in part due to adipose dysfunction, have been shown to drive obesity-mediated diseases. Similarly, elevated purines and uric acid, a degradation product of purine metabolism, are found in the bloodstream and in adipose tissue. These metabolic changes are correlated with metabolic syndrome, but little is known about the physiological effects of targeting purine biosynthesis. MethodsTo determine the effects of purine biosynthesis on organismal health we treated mice with mizoribine, an inhibitor of inosine monophosphate dehydrogenase 1 and 2 (IMPDH1/2), key enzymes in this pathway. Mice were fed either a low-fat (LFD; 13.5% kcal from fat) or a high-fat (HFD; 60% kcal from fat) diet for 30 days during drug or vehicle treatment. We ascertained the effects of mizoribine on weight gain, body composition, food intake and absorption, energy expenditure, and overall metabolic health. ResultsMizoribine treatment prevented mice on a HFD from gaining weight, but had no effect on mice on a LFD. Body composition analysis demonstrated that mizoribine significantly reduced fat mass but did not affect lean mass. Although mizoribine had no effect on lipid absorption, food intake was reduced. Furthermore, mizoribine treatment induced adaptive thermogenesis in skeletal muscle by upregulating sarcolipin, a regulator of muscle thermogenesis. While mizoribine-treated mice exhibited less adipose tissue than controls, we did not observe lipotoxicity. Rather, mizoribine-treated mice displayed improved glucose tolerance and reduced ectopic lipid accumulation. ConclusionsInhibiting purine biosynthesis prevents mice on a HFD from gaining weight, and improves their metabolic health, to a significant degree. We also demonstrated that the purine biosynthesis pathway plays a previously unknown role in skeletal muscle thermogenesis. A deeper mechanistic understanding of how purine biosynthesis promotes thermogenesis and decreases food intake may pave the way to new anti-obesity therapies. Crucially, given that many purine inhibitors have been FDA-approved for use in treating various conditions, our results indicate that they may benefit overweight or obese patients. HighlightsO_LIA purine biosynthesis inhibitor, mizoribine, protects against diet-induced weight gain C_LIO_LIMizoribine prevents fat mass gain in high-fat diet-fed male mice C_LIO_LIMizoribine reduces food intake and increases thermogenesis C_LIO_LIMizoribine induces expression of sarcolipin, a regulator of thermogenesis C_LIO_LIMizoribine treatment reduces ectopic lipids and increases glucose tolerance C_LI

physiology↗